Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057438 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL40222 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL23291324 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL30427254 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL12595158 | 0.95 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL11792668 | 0.95 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL26322291 | 0.95 | MEN1 (0.62) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL8767213 | 0.95 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL21169045 | 0.95 | MEN1 (0.58) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL705381 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20120107701-A1 | ELECTROLYTE SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTE SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120107701-A1 | ELECTROLYTE SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTE SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | MEN1 2317/4885KMT2A 1975/4885TSHR 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.